Study summary
A targeted pill slowed growth of aggressive meningiomas with specific gene changes
10 momedian progression-free survival
What was tested
Abemaciclib, a CDK4/6 inhibitor pill from breast cancer, for recurrent or progressive grade 2 or 3 meningiomas with NF2 mutations or CDK-pathway changes, in a National Cancer Institute gene-matched trial.
What they found
- Median progression-free survival was 10 months and median survival 29 months.
- The trial matches each tumor's gene changes to a specific drug.
What it means
One of the first targeted drugs to show activity in aggressive meningiomas, which have no approved drug treatment.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.